Patents Assigned to Scripps Research Institute
  • Patent number: 12329992
    Abstract: This disclosure relates to antibodies and antigen binding fragments that specifically bind Ebola virus particles. In certain embodiments, the antibodies and fragments are capable of treating or preventing an Ebola viral infection. In certain embodiments, the antibodies and antigen binding fragments are also contemplated for diagnostic methods and compositions related thereto.
    Type: Grant
    Filed: June 9, 2023
    Date of Patent: June 17, 2025
    Assignees: Emory University, The Scripps Research Institute
    Inventors: Rafi Ahmed, Carl Davis, Erica Ollmann Saphire
  • Patent number: 12312396
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: June 5, 2024
    Date of Patent: May 27, 2025
    Assignees: Theraclone Sciences, Inc., International AIDS Vaccine Initiative, Inc., The Scripps Research Institute.
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
  • Patent number: 12281137
    Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.
    Type: Grant
    Filed: February 22, 2023
    Date of Patent: April 22, 2025
    Assignee: The Scripps Research Institute
    Inventors: Floyd E. Romesberg, Denis A. Malyshev, Lingjun Li, Thomas Lavergne, Zhengtao Li
  • Patent number: 12281142
    Abstract: The present disclosure relates to recombinant HIV Env polypeptides and their use in the treatment and prevention of HIV/AIDS.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: April 22, 2025
    Assignees: International AIDS Vaccine Initiative, Inc., The Scripps Research Institute
    Inventors: Jon M. Steichen, William R. Schief
  • Patent number: 12269869
    Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: April 8, 2025
    Assignee: The Scripps Research Institute
    Inventors: Travis S. Young, Leonard Presta, David Rodgers, Eric Hampton, Timothy Wright, Peter G. Schultz, Eduardo Laborda, Elvira Khialeeva, Sophie Viaud
  • Patent number: 12263165
    Abstract: The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally-transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.
    Type: Grant
    Filed: July 11, 2023
    Date of Patent: April 1, 2025
    Assignees: The Scripps Research Institute, Board of Regents, The University of Texas System
    Inventors: Luke L. Lairson, Michael J. Bollong, Peter G. Schultz, Sendurai A. Mani
  • Patent number: 12241081
    Abstract: Methods and systems are described herein for generating engineered B cells with modified immunoglobulin genes. The modified immunoglobulin genes encode modified immunoglobulins that can have high affinity for antigens, including antigens that are variable such the types of antigens on various pathogens that can escape mammalian immune responses.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: March 4, 2025
    Assignee: The Scripps Research Institute
    Inventors: James Even Voss, Raiees Andrabi, Dennis R. Burton, Deli Huang, Alicia Gonzalez-Martin
  • Publication number: 20250051828
    Abstract: Methods and systems to functionally ablate 3? end of RNA are described. The functional ablation renders polymerases unable to initiate reverse transcription in the absence of an annealing primer. The methods and systems can be used to enhance the specificity and selectivity of cDNA generation from RNA.
    Type: Application
    Filed: December 9, 2022
    Publication date: February 13, 2025
    Applicants: Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute, The Scripps Research Institute
    Inventors: Christian Matias Gallardo Garcia Freire, Bruce E. Torbett
  • Patent number: 12209284
    Abstract: By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and/or interstitial fibrosis and tubular atrophy CAN/IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and/or subtyping of CAN/IFTA.
    Type: Grant
    Filed: May 25, 2023
    Date of Patent: January 28, 2025
    Assignee: The Scripps Research Institute
    Inventors: Daniel R. Salomon, Sunil M. Kurian, Steven R. Head
  • Patent number: 12195762
    Abstract: The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: January 14, 2025
    Assignee: The Scripps Research Institute
    Inventors: Tongxiang Lin, Sheng Ding
  • Patent number: 12173291
    Abstract: Disclosed herein are methods, cells, engineered microorganisms, and kits for increasing the production of polypeptides comprising one or more unnatural amino acids. Further provided are cells, engineered microorganisms, and kits for increasing the retention of unnatural nucleic acids encoding the unnatural amino acids in an engineered cell, or semi-synthetic organism.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: December 24, 2024
    Assignee: The Scripps Research Institute
    Inventors: Floyd E. Romesberg, Michael P. Ledbetter, Rebekah J. Karadeema
  • Patent number: 12109261
    Abstract: The present invention provides novel engineered influenza hemagglutinin (HA) proteins, related polynucleotide sequences, and vaccine compositions including nanoparticle compositions. Relative to a wildtype HA protein, the engineered HA proteins are stabilized via substitutions of one or more conserved residues in the HA2 ectodomain with hydrophobic residues. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating influenza viral infections.
    Type: Grant
    Filed: May 22, 2024
    Date of Patent: October 8, 2024
    Assignee: The Scripps Research Institute
    Inventors: Linling He, Jiang Zhu, Ian A. Wilson, Yi-Zong Lee
  • Patent number: 12077558
    Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
    Type: Grant
    Filed: February 10, 2023
    Date of Patent: September 3, 2024
    Assignees: Bristol-Myers Squibb Company, The Scripps Research Institute
    Inventors: Michael Anthony Schmidt, Bin Zheng, Kyle Knouse, Justine deGruyter, Martin D. Eastgate, Phil Baran, William R. Ewing, Richard E. Olson, Ivar M. McDonald
  • Patent number: 12018067
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: January 6, 2023
    Date of Patent: June 25, 2024
    Assignees: International AIDS Vaccine Initiative, Inc., The Scripps Research Institute, Theraclone Sciences, Inc.
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
  • Publication number: 20240191301
    Abstract: Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in solid organ transplant recipients, such as kidney transplant recipients. Methods described herein may involve combined assessment of blood gene expression profiles from an assessment of particular, related mRNA transcript levels and donor-derived cell-free nucleic acids (dd-cfDNA).
    Type: Application
    Filed: January 26, 2024
    Publication date: June 13, 2024
    Applicants: Northwestern University, Transplant Genomics, Inc., The Scripps Research Institute
    Inventors: John Friedewald, Michael M. Abecassis, Rohita Sinha, Sook Hyeon Park, Lihui Zhao, Juston Weems, Sunil M. Kurian, Steve Kleiboeker
  • Patent number: 11998602
    Abstract: This invention provides novel methods for treating or ameliorating symptoms of demyelinating diseases such as multiple sclerosis. The methods involve administering to subjects in need of treatment a pharmaceutical composition that contains a therapeutically effective amount of taurine and also a compound that induces oligodendrocyte precursor cell (OPC) differentiation (e.g., T3, benztropine, clemastine or miconazole). Some of the methods additionally involve administration to the subject a known agent for treating demyelinating diseases (e.g., SIP receptor agonists) or a known disease modifying drug. The invention also provides methods for increasing myelination and methods for promoting OPC differentiation into oligodendrocytes. These methods entail contacting a population of OPCs with a combination of taurine and a known OPC differentiation-inducing agent such as T3, clemastine, benztropine or miconazole.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 4, 2024
    Assignee: The Scripps Research Institute
    Inventors: Luke Lairson, Brittney Beyer, Mingliang Fang, Gary Siuzdak
  • Publication number: 20240158403
    Abstract: The present disclosure provides novel heteroaryl compounds of formula (IX). Such compounds are useful for the treatment of cancers.
    Type: Application
    Filed: January 24, 2024
    Publication date: May 16, 2024
    Applicants: Dana-Farber Cancer Institute, Inc., The Scripps Research Institute
    Inventors: Nathanael S. GRAY, Jianming ZHANG, Barun OKRAM, Xianming DENG, Jae Won CHANG, Amy WOJCIECHOWSKI
  • Patent number: 11970525
    Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family ?-receptor 4 (GFR?4).
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: April 30, 2024
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG, The Scripps Research Institute
    Inventors: Donald L. Siegel, Michael C. Milone, Vijay Bhoj, Christoph Rader
  • Patent number: 11964010
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: April 23, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason Mclellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Patent number: RE50268
    Abstract: The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 ?g/ml, compositions containing the same and uses thereof.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: January 14, 2025
    Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute, Cornell University
    Inventors: Dennis R. Burton, Marit J. Van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok